These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Biosimilars in Dermatology: Current Situation (Part II).
    Author: Puig L, Carretero G, Daudén E, Ferrándiz C, Marrón SE, Martorell A, Pérez-Suárez B, Rodriguez-Cerdeira C, Ruiz-Villaverde R, Sánchez-Carazo JL, Velasco M, en nombre del Grupo de Psoriasis de Academia Española de Dermatología y Venereología.
    Journal: Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964.
    Abstract:
    The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more biosimilars can be expected to follow in the coming months and years. Logically, this new situation will have economic repercussions and alter prescribing patterns among dermatologists. In this second part of the review, we will look at several somewhat contentious issues, such as the extrapolation of indications, interchangeability, and automatic substitution. We will also review the biosimilars with indications for psoriasis currently in the clinical development pipeline and assess their potential to offer comparable efficacy and safety to the reference product while contributing to the sustainability of the public health care system.
    [Abstract] [Full Text] [Related] [New Search]